Conversely, cervical cancer cell growth in vivo could be stopped by ETAR blockade with Atrasentan (ABT-627), a selective ETAR-inhibitor, alone, and in that study Atrasentan displayed additive antitumour effects when administered in combination with the cytotoxic agent Paclitaxel (Bagnato et al, 2002). This evidence concerns the gene EDNRA and cervical carcinoma.